Senesco Contracts Criterium for Multiple Myeloma Study

Criterium, a full-service, global CRO, has been selected to manage the operational aspects of Phase Ib/IIa trial of SNS01-T, a lead therapeutic candidate for the treatment of multiple myeloma.

Senesco Technologies announced Monday it has selected Criterium, Inc. to manage the operational aspects of its Phase Ib/IIa clinical study of SNS01-T, its lead therapeutic candidate for the treatment of multiple myeloma. The study is expected to start in the third quarter.

The Senesco team recently met with counterparts at Criterium to finalize the operational plans for the conduct and analysis of this open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.

The study design calls for twice-weekly dosing of patients for six weeks followed by a four-week safety data review period before escalating to a higher dose